Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Abivax
ISIN US00370M1036
|WKN A3EWCP
Market cap (in EUR)
8,310 m
Country
France
Sector
Healthcare
Overview
Description
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals France
Financials
Key metrics
| Market capitalisation, EUR | 8,310 m |
| EPS, EUR | -4.79 |
| P/B ratio | 17.8 |
| P/E ratio | - |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | - |
| Net income, EUR | -336 m |
| Profit margin | - |
What ETF is Abivax in?
There is 1 ETF which contains Abivax.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.53% | Equity United States Health Care Biotech | 49 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.